The introduction of combination antiretroviral therapy (cART) drastically improved performance status, immune function, and life expectancy of HIV‐infected individuals. In addition, incidence of opportunistic infections and of AIDS‐defining malignancies declined. Nevertheless, aggressive non‐Hodgkin’s lymphoma still remains the leading cause of AIDS‐related deaths. The availability of cART, however, significantly improved the therapeutic options for HIV‐positive patients with lymphomas. Diffuse large B‐cell lymphoma, Burkitt’s lymphoma, or Hodgkin lymphoma has increasingly become curable diseases. In light of these favorable developments in the treatment of HIV and HIV‐associated lymphomas, reduction in treatment‐associated toxicities and further improvement of outcome of patients with advanced immune suppression are major requirements for future clinical trials. This review summarizes the current treatment landscape and gives an overview on future needs in HIV‐positive patients with lymphoma.

Competition among reagents in dynamic combinatorial libraries of increased complexity leads to reactional self-sorting. This fundamental principle allowed development of selective dynamic protecting groups for controlled sequential derivatization of polyamines.

No abstract

A short route for the syntheses of methyl‐substituted hydroxycyclohexenones, which are building blocks for various natural products, is presented. Both oxygen atoms were introduced as acetates by a palladium(II)‐catalyzed 1,4‐addition to a 1,3‐diene. The distinction between the two acetoxy groups was achieved by regioselective monohydrolysis with lipase from Candida rugosa, which gave 1‐acetoxy‐4‐hydroxy‐5‐methylcyclohexene and its 6‐methyl regioisomer as a separable mixture. The target compounds 4‐hydroxy‐5‐methylcyclohex‐2‐enone and 4‐hydroxy‐6‐methylcyclohex‐2‐enone could then be obtained as diastereomeric mixtures in good overall yields and with moderate enantiomeric excesses (31–67 %).